---
title: "Alnylam Pharmaceuticals Announces Positive HELIOS-B Phase 3 Results for AMVUTTRA® (Vutrisiran), Showing Reduced GI Events in ATTR-CM Patients"
description: "Alnylam Pharmaceuticals Inc. announced positive results from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), showing a 37-49% reduction in gastrointestinal adverse events compared to placebo in "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259221661.md"
published_at: "2025-09-28T15:13:19.000Z"
---

# Alnylam Pharmaceuticals Announces Positive HELIOS-B Phase 3 Results for AMVUTTRA® (Vutrisiran), Showing Reduced GI Events in ATTR-CM Patients

> Alnylam Pharmaceuticals Inc. announced positive results from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), showing a 37-49% reduction in gastrointestinal adverse events compared to placebo in ATTR-CM patients. The findings, presented at the HFSA Annual Scientific Meeting 2025, support the safety and efficacy of vutrisiran and its recent approvals in multiple regions, including the US and EU.

Alnylam Pharmaceuticals Inc. has announced new analyses from the HELIOS-B Phase 3 study evaluating AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of wild-type or hereditary transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) and hereditary transthyretin-mediated amyloidosis with polyneuropathy (hATTR-PN) in adults. The results, which were presented at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025, indicate that vutrisiran treatment was associated with 37-49% lower rates of gastrointestinal adverse events compared to placebo across multiple treatment groups. The findings also reinforce the safety and efficacy profile of vutrisiran as a monotherapy and demonstrate a consistent benefit across a range of patient baseline characteristics. These data support the recent approvals of AMVUTTRA for ATTR-CM in several regions, including the United States, European Union, Japan, Brazil, UAE, and the United Kingdom. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250928990563) on September 28, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [ALNY.US - Alnylam Pharma](https://longbridge.com/en/quote/ALNY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| An Overview of Alnylam Pharmaceuticals's Earnings | Alnylam Pharmaceuticals (NASDAQ:ALNY) is set to announce its quarterly earnings on February 12, 2026, with analysts pred | [Link](https://longbridge.com/en/news/275625964.md) |
| Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) added to NASDAQ-100 Index | Alnylam Pharmaceuticals, Inc Added to NASDAQ-100 Index. | [Link](https://longbridge.com/en/news/270482423.md) |
| A Look At BioCryst Pharmaceuticals (BCRX) Valuation After New Hereditary Angioedema Data And Conference Spotlight | BioCryst Pharmaceuticals (BCRX) has gained attention following the announcement of nine hereditary angioedema presentati | [Link](https://longbridge.com/en/news/275698599.md) |
| Tectonic Therapeutic Hosts Virtual KOL Event Showcasing TX2100 for Hereditary Hemorrhagic Telangiectasia | Tectonic Therapeutic Inc. (NASDAQ: TECX) will host a virtual KOL event on TX2100, a new treatment for Hereditary Hemorrh | [Link](https://longbridge.com/en/news/275655792.md) |
| AI CEO warns AI's disruption will be 'much bigger' than COVID: 'The people I care about deserve to hear what is coming' | AI CEO warns AI's disruption will be 'much bigger' than COVID: 'The people I care about deserve to hear what is coming' | [Link](https://longbridge.com/en/news/275641811.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.